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A double· blind crossover trial comparing diltiazem (360 
mg/day) and nifedipine (120 mg/day) for treatment of stable 
angina was conducted in 21 of 27 patients with proven 
coronary artery disease who completed the trial. All pa· 
tients started with a 2 week placebo period followed by a 
random assignment to either drug treatment for 3 weeks 
and subsequent crossover to the other treatment. The two 
drug treatment periods were separated by a 1 week placebo 
washout phase and the study was completed with a 1 week 
placebo phase. There were no significant differences be· 
tween patients' responses to diltiazem and nifedipine in 
relation to time to onset of angina, ST depression responses 
to exercise, heart rate or systolic or diastolic blood pres· 
sure. 
A total of 37 adverse effects were reported with nifedJ· 
pine compared with 9 with diltiazem in the 22 patients in 
whom drug safety was analyzed. Additionally, two patients 
treated with nifedipine were withdrawn from study partic· 
ipation before crossover. There was a significant (p < 0.05) 
The antianginal effects of calcium channel blockers have 
been well established. Calcium channel blockers are charac-
terized by diverse chemical structure and properties (1). 
Three drugs in this class are available in Canada for clinical 
use: nifedipine, verapamil and diltiazem. The vasodilating 
effects of these drugs are believed to cause the beneficial 
results observed in patients with stable angina. Peripheral 
vascular resistance is decreased, leading to a decrease in 
work load that in turn lessens myocardial oxygen demand. 
An increase in coronary blood flow due to coronary artery 
dilation results in increased myocardial oxygen supply (2). 
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difference with respect to incidence of edema (7 of 22 
patients taking nifedipil1e, 1 of 22 taking diltiazem) and 
dizziness (7 of 22 patients taking nifedipine, 0 of 22 taking 
diltiazem). The most frequent adverse effect reported with 
diltiazem was rash (3 of 22 patients). Severe adverse effects 
were reported in four patients: in one with diltiazem (rash) 
and in three with nifedipine (palpitation in two and head· 
ache in one). A reduction in prescribed dosage was required 
in 37% of nifedipine·treated compared with 6% of diltia· 
zem·treated patients. 
Efficacy measures were significantly improved abo)'e 
placebo levels by both diltiazem and nifedipine. There was 
no difference between these two drugs in terms of exercise 
stress test efficacy. Diltiazem significantly reduced the 
weekly angina frequency (p < 0.001). The incidence of 
adverse reactions was significantly lower with diltiazem 
than with nifedipine. 
(J Am Coll CardioI1988;12:1562-7) 
Although these three calcium channel blockers share these 
basic properties, there is substantial variation in their effects 
on the coronary vasculature as compared with the peripheral 
vessels and the heart (3,4). 
This study compared, in a prospective, randomized, 
double-blind crossover design, the efficacy and safety of 
diltiazem hydrochloride and nifedipine in patients with sta-
ble angina. Special attention was given to the effect of the 
two drugs on exercise performance, the frequency of anginal 
episodes and tolerability. 
Methods 
The protocol was approved by the Ethics Committee of 
our institution, and each patient consented in writing to 
participate in the study. 
Design. The study consisted of a qualification phase to 
determine eligibility for the study, a placebo washout phase 
of 1 week's duration, and two 3 '"leeK double-blind crossover 
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treatment phases in which patients took either diltiazem or 
nifedipine separated by a placebo washout phase of 1 week's 
duration and followed by a third placebo washout phase of 1 
week's duration. 
Selection of patients. All patients entering the study were 
required to have 1) a history of stable angina pectoris for 2:3 
months before study entry and documented coronary artery 
disease (2:70% stenosis in at least one major coronary 
artery); 2) episodes of angina (precordial chest pain, pres-
sure or distress) precipitated by exercise or emotional stress 
and relieved by sublingual nitroglycerin, rest or removal of 
the stress (physical or emotional); and 3) 2: 1 mm horizontal 
ST segment depression from baseline accompanied by typi-
cal pain on exercise stress testing or 2 mm ST segment 
depression in the absence of pain. 
Patients were excluded from consideration if they had 1) 
unstable angina or a history of unresponsiveness to sublin-
gual nitroglycerin; 2) myocardial infarction ::;3 months be-
fore study entry; 3) other cardiac disease; 4) arrhythmias; 5) 
other conditions that significantly limit ability to exercise; 6) 
hypotension (systolic blood pressure ::;80 mm Hg) or hyper-
tension (diastolic blood pressure 2:100 mm Hg); 7) emotional 
instability; 8) significant renal, hepatic, endocrine, hemato-
logic or neurologic disease; 9) known hypersensitivity to 
diltiazem or nifedipine; or 10) concurrent therapy with any of 
the following medications: vasodilators, beta-adrenergic 
blockers, digitalis glycosides, phenothiazines, tricyclic anti-
depressants or any drugs that significantly affect the electro-
cardiogram (ECG) at baseline. Twenty-seven patients ful-
filled these criteria and were entered into the study. 
Protocol. At least 72 h had elapsed between the last dose 
of any antianginal medication and the first qualifying or 
baseline exercise stress test. However, sublingual nitroglyc-
erin usage was permitted up to 2 h before testing. A 12 lead 
ECG at rest, laboratory analysis and physical examination 
were also performed during the qualifying phase. At the 
completion of a 1 week placebo period (two placebo capsules 
three times a day), patients had a second qualifying treadmill 
test. If these results were within 20% of the first baseline test 
the patients were then randomized in blinded fashion to 
therapy with either diltiazem or nifedipine. During the 3 
week treatment phases, therapy was initiated with one 
capsule three times a day (30 mg diltiazem capsule or 10 mg 
nifedipine capsule) and titrated to maximal dosage (four 
capsules three times a day) over the next 7 days. Maximal 
dosage was determined by side effects. If only mild or no 
side effects were experienced, the maximal dosage of 360 mg 
diltiazem or 120 mg nifedipine/day was achieved. However, 
in the event of anginal pain or adverse experiences the 
dosage was adjusted as required. During the last 2 weeks of 
each treatment phase, the dose of study medication re-
mained stable. 
Patients were provided with a diary to record anginal 
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episodes, nitroglycerin consumption and side effects during 
all placebo and active treatment phases. Patients were 
assessed at the end of each of these phases on the basis of 
results of an exercise stress test, an ECG at rest, a review of 
the diaries and adverse experiences reported. One final 
laboratory analysis was performed at the last evaluation. 
Concomitant medications. Concomitant medications pro-
hibited during the study, as defined in the exclusion criteria, 
could not be used during the 72 h period before the first 
exercise test. Other medications necessary for the welfare of 
the patient could be continued at a stable dose. 
Exercise testing. Patients underwent treadmill exercise 
testing according to the Bruce protocol (5). Exercise was 
terminated at the point when the patient would stop during 
daily life because of symptoms of anginal chest pain (3 on an 
anginal scale of 5), shortness of breath, fatigue or leg 
discomfort. In the absence of pain, 2 mm of ST segment 
change was utilized as a terminal end point. Treadmill 
exercise testing was performed as previously described 
(before study, in the qualifying period, at the end of each 
active treatment period, at the end of the crossover washout 
period and in the final washout period) at the same time of 
day ±2 h. In each treadmill test the following end points 
were measured: time to onset of angina, time to onset of 1 
mm ST segment depression, time to maximal ST depression 
and maximal work load. In addition, computer-averaged 
ECG complexes from leads II, V 5 and a VF were obtained (to 
the nearest minute). Heart rate was recorded at 1 min 
intervals and blood pressure was recorded at the end of each 
stage. Horizontal or downsloping ST segment depression 2: 1 
mm from the J point was considered to be significant for 
ischemia. The real time 12 lead ECG recordings at each 
minute, and at the onset of 1 mm of ST depression and 
maximal work load were compared with this signal-averaged 
recording, If the computer-generated signal was not concor-
dant with the real time recording, the latter was used for 
analysis. 
Statistical analysis. Analysis of variance appropriate to 
the crossover design (6) was used to compare diltiazem with 
nifedipine with respect to each variable. Repeated measures 
analysis of variance (6) revealed no significant (p < 0.05) 
differences among the three washout periods with respect to 
the mean values of any of the variables measured. Two-way 
analysis of variance was used to compare the response to 
diltiazem and nifedipine with the mean response to the three 
washout periods. Because there was an imbalance in the 
number of patients who received the treatments in each 
order (diltiazem-nifedipine, nifedipine-diltiazem), the mean 
treatment differences were adjusted for period effects. 
The crossover analysis of the exercise stress test varia-
bles (heart rate, blood pressure and ST segment change) at 
the onset of angina or 1 mm ST depression included only 
those subjects who experienced angina or 1 mm ST depres-
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Table 1. Demographic and Clinical Characteristics of 21 Patients 
Age (yr) (mean ± SO) 
Weight (kg) (mean ± SD) 
Gender (male/female) 
Positive history of smoking* 
Positive history of myocardial infarction 
Duration of angina « I yr) 
*Not recorded in 2 patients. 
57.2 ± 7.2 




sion under both treatment conditions. In addition to the 
analysis of variance, Koch's nonparametric analysis (7) was 
used to compare the active treatments in all 21 subjects who 
completed the study by assigning minimal or maximal rank 
to subjects in whom a response could not be defined. If 
angina did not occur during the exercise stress test, a 
maximal rank was assigned. Similarly, if 1 mm ST depres-
sion was present at baseline, a minimal rank was assigned for 
the time to 1 mm ST depression analysis. 
The binominal test for paired samples (8) was used to 
compare the active treatments with respect to the incidence 
of adverse effects. Nonparametric analysis was performed to 
confirm the parametric results. Analyses were carried out 
using the SAS package. All p values reported are two-tailed 
and the level of significance applied is 0.05. 
Results 
Study patients. Of the 27 patients who entered the trial, 3 
were withdrawn prematurely during washout phase 1 (2 for 
medical reasons [angioplasty and diabetic management, re-
spectively] and 1 for refusal to continue) and were consid-
ered ineligible for analysis. In addition, two patients were 
withdrawn during treatment phase 1 (one because of a severe 
adverse event and the other because of refusal to continue) 
and a third patient was withdrawn because of a severe 
adverse reaction during treatment phase 2 before the exer-
cise stress test was carried out. These three patients were 
eligible for drug safety analysis only, because they did not 
undergo the exercise treadmill test under both treatment 
conditions. Thus, 21 patients were eligible for drug efficacy 
analysis. 
Demographic and clinical findings. The demographic and 
clinical characteristics of the 21 eligible patients are dis-
played in Table 1. Before study entry 13 patients had ~7 
anginal attacks/week, 3 had 8 to 21 attacks/week and five had 
>21 attacks/week. 
The pre study treatment regimens included a calcium 
channel blocker in 10 patients, a beta-blocker in 7 and 
nitrates (excluding sublingual nitroglycerin) in 4. As men-
tioned, all of these medications were discontinued ~72 h 
before the pre study exercise stress testing. 
All 21 patients exercised to an angina-limited end point at 
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Table 2. Stress Electrocardiographic Values: Comparison of 
Washout With Treatment Phases (mean ± SD) 
Washout* Diltiazem Nifedipine 
Time (min) to 
Onset of angina 3.4 ± 1.6 4.7 ± 1.9 4.2 ± 2.2 
I mm ST depression 3.3 ± 1.4 3.7 ± 2.1 3.9 ± 1.7 
Max ST depression 6.0 ± 2.1 6.8 ± 2.1 6.8 ± 2.3 
Max work load 6.0 ± 2.2 6.9 ± 2.3 7.0 ± 2.4 
Recovery 9.9 ± 0.9 10.1 ± 0.3 10.1 ± 0.3 
ST segment change (mm) at 
Onset of angina - 1.\1 ± 0.56 -1.35 ± 0.56 - 1.04 ± 0.56 
I mm ST depression -1.13 ± 0.30 -1.03 ± 0.20 -1.14 ± 0.31 
Max ST depression -2.03 ± 0.83 - 1.98 ± 0.81 -1.88 ± 0.76 
Max work load -2.00 ± 0.84 - 1.97 ± 0.81 - 1.84 ± 0.77 
Recovery -0.24 ± 0.43 -0.19 ± 0.39 -0.35 ± 0.51 
*Mean of values for three washouts phases; max = maximal. 
qualification. Additional reasons for exercise termination 
were ST segment change in one, premature ventricular 
complexes in one, and shortness of breath in one. 
Dosage. The maximal doses of diltiazem and nifedipine 
administered were 360 and 120 mg/day, respectively. The 
mean values (± SD) of the titrated doses were 339 ± 48 mg/ 
day of diltiazem and 76 ± 37 mg/day of nifedipine. 
Frequency of anginal episodes. The weekly frequency of 
anginal episodes was 4.0 ± 6.8 with diltiazem, which was 
significantly lower (p = 0.01) than that with nifedipine (5.5 ± 
8.2) as determined by an analysis of variance. The frequency 
of anginal episodes with diltiazem was also significantly 
lower (p = 0.006) than that during the average of the three 
placebo washout phases (6.9 ± 9.3), but there was no 
significant difference when nifedipine was compared with the 
average of the washout phases. Analysis of variance for the 
crossover design revealed a trend (p = 0.08) for the mean 
percent of pain-free days to be higher with diltiazem (70.3 ± 
31.6%) than with nifedipine (61.6 ± 30.6%). The percent of 
pain-free days was significantly greater with diltiazem than 
with placebo (p < 0.001); however, a comparison of nifedi-
pine with placebo showed only a trend toward significant 
improvement with this drug (p = 0.06). 
Effects on exercise performance (Tables 2 and 3). Analysis 
of variance showed no significant differences between diltia-
zem and nifedipine for time to onset of angina, 1 mm ST 
segment depression, maximal ST depression and maximal 
work load (Table 2). There were also no significant differ-
ences between treatments for systolic or diastolic blood 
pressure or rate-pressure product under each condition. 
Heart rate at rest was significantly lower (p < 0.01) for 
diltiazem (64.1 ± 9.6) than for nifedipine (70.0 ± 10.9) (Table 
3). There were no other significant differences in heart rate 
between treatments during exercise stress testing. However, 
ST depression at the onset of angina showed a tendency (p = 
0.08) to be greater during the diltiazem treatment phase 
JACC Vol. 12, No.6 
December 1988:1562-7 
KLINKE ET AL. 1565 
D1LTIAZEM VERSUS NIFEDIPINE IN STABLE ANGINA 
Table 3. Stress Heart Rate and Blood Pressure Values: Comparison of Washout With Treatment 
Phases (mean ± SD) 
Washout* Diltiazem Nifedipine 
Heart rate (beats/min) at 
Rest 71.1 ± 11.2 64.1 ± 9.6 70.0 ± 10.9 
Onset of angina 108.7 ± 9.3 109.6 ± 11.1 109.9 ± 13.3 
1 mm ST depression 109.2 ± 10.7 105.3 ± 12.9 108.7 ± 11.8 
Max ST depression 124.2 ± 11.8 120.7 ± 11.9 125.0 ± 16.4 
Recovery 73.8 ± 12.3 72.0 ± 10.4 77.8 ± 16.4 
Systolic blood pressure (mm Hg) at 
Rest 135.0 ± 17.1 131.3 ± 17.0 130.8 ± 14.6 
Onset of angina 156.8 ± 19.4 156.9 ± 16.2 159.6 ± 23.7 
1 mm ST depression 155.1 ± 17.9 154.5 ± 17.2 156.3 ± 22.0 
Max ST depression 166.6 ± 17.9 168.6 ± 18.3 165.4 ± 21.3 
Recovery 131.8 ± 20.0 127.1 ± 16.8 127.6 ± 16.4 
Diastolic blood pressure (mm Hg) at 
Rest 79.5 ± 12.0 77.0 ± 11.6 72.5 ± 11.3 
Onset of angina 88.8 ± 8.9 84.0 ± 9.6 84.7 ± 12.9 
1 mm ST depression 87.2 ± 9.0 83.1 ± 9.0 83.1 ± 13.1 
Max ST depression 93.5 ± 8.3 88.9 ± 11.6 89.3 ± 9.9 
Recovery 79.6 ± 11.5 72.3 ± 11.5 75.2 ± 11.2 
Rate pressure product (heart rate x 
systolic blood pressure) 
Rest 8,510 ± 2,107 9,240 ± 2,193 9,680 ± 2,720 
I mm ST depression 16,311 ± 3,030 16,943 ± 2,738 16,816 ± 3,046 
Max ST depression 20,412 ± 3,467 20,794 ± 4,331 20,832 ± 4,029 
*Mean of values for three washout phases. Abbreviations as in Table 2. 
(-1.35 ± 0.56 mm) than during the nifedipine treatment 
phase (-1.04 ± 0.56 mm). The mean recovery heart rate was 
significantly lower (p = 0.04) during diltiazem treatment 
(72.0 ± 10.4 beats/min) than during nifedipine treatment 
(77.8 ± 16.4 beats/min). The mean ST depression was also 
significantly lower in recovery (p = 0.03) during diltiazem 
treatment (-0.19 ± 0.39 mm) than during nifedipine treat-
ment (-0.35 ± 0.51 mm). 
patients were taking aspirin. All of these medications were 
permissible under the protocol and were continued at a 
stable dose throughout the study. 
There were no significant differences among the three 
washout phases for any variable. When the average of the 
washout periods was compared with diltiazem and nifedipine 
for each variable, it was found that the mean time to onset of 
angina, 1 mm ST segment change, maximal ST depression 
and maximal work load were significantly greater with the 
active treatments. 
Reasons for stopping exercise testing after both the 
diltiazem and the nifedipine phases were similar, with 14 
patients from each phase having angina pectoris alone. Other 
reasons for stopping included fatigue, shortness of breath, 
leg fatigue, angina and ST segment change or angina and 
ventricular begiminy. 
Compliance. Pill counts were performed at every visit to 
assess compliance. Compliance to the titrated dose ranged 
from 89 to 95%. Two patients did not return their unused 
medication. There were no differences between the treat-
ments with respect to the compliance rate. 
Concomitant medications. A variety of other medications 
were used during the study; approximately a third of the 
Adverse reactions (Table 4). Of the 22 patients who 
received both treatments, 7 (32%) experienced adverse 
effects with diltiazem compared with 19 (86%) with nifedi-
pine (p < 0.001). Specific adverse effects that showed 
significant treatment differences (p = 0.008) were dizziness 
(none with diltiazem and seven with nifedipine) and edema 
of the ankles and feet (one with diltiazem and seven with 
nifedipine, p = 0.02). A severe adverse effect occurred in 
Table 4. Adverse Effects and Their Severity in 22 Patients 
Receiving Both Drug Treatments 
Adverse Effect Diltiazem Nifedipine 
Edema* I (mod) 7 (mod) 
Dizziness* 0 7 (1 mild, 6 mod) 
Flushing 0 4 (mod) 
Palpitation 0 3 (1 mod, 2 severe) 
Nausea 0 3 (1 mild, 2 mod) 
Rash 3 (2 mod, I severe) 0 
Headache 2 (1 mild, I mod) 2 (1 mod, 1 severe) 
Fatigue 2 (mild) 1 (mod) 
Light-headedness 0 2 (mod) 
Bloated feeling 0 2 (mod) 
Other I (mod) 6 (1 mild, 5 mod) 
Total* 9 37 
*p < 0.05. Mod = moderate. 
1566 KLINKE ET AL. 
DlLTIAZEM VERSUS NIFEDlPINE IN STABLE ANGiNA 
one patient with diltiazem (rash) and in three with nifedipine 
(palpitations in two and headache in one). 
In addition to the 22 patients who received both treat-
ments, there were 2 patients who were withdrawn from the 
study after receiving nifedipine only. One of these two 
patients developed unstable angina and was hospitalized and 
the other reported moderate dizziness and flushing and 
refused to continue in the study. All abnormal laboratory 
values were considered to be of no clinical significance or 
unrelated to study treatments. Because of adverse effects, 
the dosage of nifedipine needed to be reduced from 12 
capsules/day to a mean of7.6 ± 3.7 capsules/day or 76 ± 37 
mg/day, whereas the mean dosage of diltiazem used was 11.3 
± 1.6 capsules/day of 339 ± 48 mg/day. The side effects of 
nifedipine necessitated a 37% reduction in the dosage, 
whereas those associated with diltiazem resulted in a 6% 
reduction (p < 0.001). 
Discussion 
Antianginal effects of diltiazem and nifedipine. The bene-
ficial results with calcium channel blockers observed in 
patients with stable angina are probably due to the vasodi-
lating effect of these drugs. Peripheral vascular resistance is 
decreased, leading to a decrease in work load that, in turn 
lessens myocardial oxygen consumption. An increase in 
coronary blood flow due to coronary dilation results in 
increased myocardial oxygen supply. 
Diltiazem hydrochloride and nifedipine are currently used 
in patients with vasospastic, unstable or chronic stable 
angina. There is substantial variation in the effects of these 
two calcium channel blockers on the coronary vasculature 
compared with the peripheral vasculature and the heart. 
Diltiazem has a potent effect on the coronary arteries but its 
effects on the peripheral vasculature and myocardium are 
moderate; in contrast, nifedipine is a potent peripheral 
vasodilator in doses that dilate the coronary arteries 0-3). 
Studies in dogs have demonstrated that diltiazem dilates 
both the large conductance arteries and the arterioles of the 
coronary vasculature. In contrast, nifedipine dilates only the 
arterioles (3). 
Whereas all calcium channel blockers depress myocardial 
contractile force (negative inotropic effect) in isolated tis-
sues, they may do so in significantly different degrees. Data 
suggest that calcium channel blockers vary in their propen-
sity to reduce left ventricular function and that the myocar-
dial depressant effects of these agents are partially offset by 
reflex and peripheral vascular actions (4). Diltiazem has 
clinically important effects on cardiac conductive tissues 
(sinus and atrioventricular (A V) nodes) resulting in a nega-
tive chronotropic effect and prolongation of A V conduction, 
whereas nifedipine has minimal, if any, effect. 
These differences between diltiazem and nifedipine ac-
count for the side effects that are seen. Nifedipine is more 
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likely to cause hypotension, flushing and edema. In some 
cases, reflex tachycardia may actually aggravate angina. 
Diltiazem, on the other hand, may cause problems with sinus 
bradycardia and occasionally A V block. 
Previous studies on efficacy of diltiazem. Previous studies 
have shown diltiazem, alone or in combination with other 
drugs, to be efficacious in relieving symptoms and improving 
exercise time when compared with placebo. Diltiazem (120, 
180 and 240 mg/day) versus placebo was studied in 63 
patients with stable angina (9). A decrease in the number of 
anginal attacks per week and in the use of nitroglycerin was 
demonstrated, and total exercise time was increased. There 
was, however, no significant increase in time to 1 mm ST 
segment depression or time to angina. In a similar study (10), 
a definite dose-related response was established, with 240 
mg being the most effective. At this dose, improvements in 
total exercise time, time to onset of angina and time to 1 mm 
ST depression were seen as well as reductions in heart rate, 
diastolic blood pressure and rate-pressure product at submax-
imal exercise. 
The benefit of adding diltiazem to maximal beta adrener-
gic blocker and nitrate therapy was evaluated in 12 patients 
(11). In this study, too, there was significant improvement in 
the listed exercise variables. No clinically significant adverse 
effects were seen. From these studies one can appreciate 
that diltiazem has a dose-response effect and that a dose of 
240 mg/day appears to be the most beneficial. 
Previous studies on efficacy of nifedipine. Nifedipine 
showed promising results compared with placebo in a study 
of 12 patients with stable exertional angina (2). This was a 
single-blind trial of ascending doses of nifedipine to a max-
imum of 120 mg/day versus placebo. Although there was a 
trend for improvement in work load on stress testing, 
within-patient variability in response was seen. Indeed, 
some patients developed worsening angina at the higher dose 
levels; 50% of these patients could not tolerate high dose 
nifedipine. In a single-blind controlled trial (13), a 1 min 
improvement in treadmill exercise time with 60 mg/day of 
nifedipine was reported in 10 patients treated. A decrease in 
anginal frequency and nitroglycerin consumption was also 
reported. 
Studies of nifedipine alone and in combination with 
isosorbide dinitrate or beta-blocking agents have resulted in 
similar results. However, it appears that nifedipine is most 
efficacious when used in combination with a beta-blocker 
(14-16). In summary, nifedipine has a variable beneficial 
effect in stable angina. A minimal dose of 60 mg/day is 
usually necessary; however, at higher doses, side effects and 
worsening angina may be seen. 
Comparative studies of diltiazem versus nifedipine. Three 
previous studies (17-19) comparing diltiazem with nifedipine 
have shown both drugs to be effective in patients with angina 
pectoris. Chaitman et al. (20) evaluated the different mech-
anisms of drug action and temp.oral difference in the exercise 
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hemodynamic response to single oral doses of propranolol 
(80 mg), diItiazem (120 mg) and nifedipine (20 mg). In this 
short-term drug study they tested for onset and duration of 
action at 1, 3 and 8 h after drug ingestion in patients with 
stable angina, All of these drugs significantly prolonged the 
time of onset of 1 mm ST segment depression and increased 
work capacity, The magnitude of increased work capacity 
was greater after diItiazem and nifedipine than that observed 
after propranolol. For each drug, the maximal increment in 
exercise was most marked at 3 h. At maximal exercise, 
propranolol decreased myocardial oxygen demand to a 
greater extent than diltiazem or nifedipine. The temporal 
bioavailability of diItiazem and nifedipine differs, with nifed-
ipine exerting maximal effects at 1 to 3 h after dosing and 
diltiazem at 3 to 8 h after dosing. 
In our present study, both diltiazem and nifedipine were 
shown to significantly improve exercise time and time to 1 
mm of ST segment depression compared with placebo. 
However, there was no significant difference in these time-
related variables when the two drugs were compared with 
each other. Heart rate at rest was significantly lower with 
diltiazem than with nifedipine and placebo. During maximal 
exercise, the heart rate attained was similar in all treatment 
groups. Diltiazem-treated patients showed a significant de-
crease in the frequency of weekly anginal attacks compared 
with that during treatment with nifedipine or placebo. The 
differences between nifedipine and placebo were not signif-
icant. There was also a significant difference between diltia-
zem and placebo in the number of pain-free days and a trend 
in favor of diltiazem versus nifedipine. Adverse effects were 
more frequent and severe in the nifedipine group. The major 
portion of this difference was attributable to dizziness and 
edema. 
Conclusions. Previous studies have demonstrated that 
diltiazem and nifedipine in adequate doses are efficacious in 
treating patients with stable angina pectoris. This study 
confirms the efficacy of both drugs relative to placebo, 
although the weekly number of anginal attacks was more 
significantly reduced by diltiazem. It would appear that there 
was no difference between the two drugs in the prolongation 
of exercise time and time to onset of ST depression. Diltia-
zem did cause a significant lowering of the heart rate at rest 
compared with that during treatment with nifedipine or 
placebo. Although diltiazem and nifedipine are equally effi-
cacious in patients with stable angina pectoris, diltiazem is 
better tolerated and may provide more symptomatic relief. 
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